Previous Article | Next Article ![]()
J Virol, August 1998, p. 6637-6645, Vol. 72, No. 8
Department of Microbiology, Mount Sinai
School of Medicine, New York, New York 10029
Received 16 March 1998/Accepted 18 May 1998
During secondary immune responses to influenza virus,
virus-specific T memory cells are a major source of gamma
interferon (IFN-
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Protective Role of Gamma Interferon during the
Recall Response to Influenza Virus
and
). We assessed the contribution of IFN-
to
heterologous protection against the A/WSN/33 (H1N1) virus of wild-type
and IFN-
/
mice previously immunized with the A/HK/68 (H3N2)
virus. The IFN-
/
mice displayed significantly reduced survival
rates subsequent to a challenge with various doses of the A/WSN/33
virus. This was associated with an impaired ability of the IFN-
/
mice to completely clear the pulmonary virus by day 7 after the challenge, although significant reduction of the virus titers
was noted. However, the IFN-
/
mice developed type A influenza
virus cross-reactive cytotoxic T lymphocytes (CTLs) similar to the
wild-type mice, as demonstrated by both cytotoxicity and a
limiting-dilution assay for the estimation of CTL precursor frequency.
The pulmonary recruitment of T cells in IFN-
/
mice was not
dramatically affected, and the percentage of CD4+ and
CD8+ T cells was similar to that of wild-type mice. The T
cells from IFN-
/
mice did not display a significant switch
toward a Th2 profile. Furthermore, the IFN-
/
mice retained the
ability to mount significant titers of WSN and HK virus-specific
hemagglutination-inhibiting antibodies. Together, these results are
consistent with a protective role of IFN-
during the
heterologous response against influenza virus independently of the
generation and local recruitment of cross-reactive CTLs.
*
Corresponding author. Present address: Alliance
Pharmaceutical Corp., 3030 Science Park Rd., San Diego, CA 92121. Phone: (619) 558-4300. Fax: (619) 678-4178. E-mail:
ABot{at}allp.com.
Present address: Alliance Pharmaceutical Corp., San Diego, CA
92121.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|